TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum
Key Highlights
- ➤TriSalus management to present corporate overview November 11 at 11:30 a.m. ET
- ➤TriSalus executives will hold one-on-one meetings at Canaccord Genuity forum
- ➤Nelitolimod phase 1 data completion nearing, with partnership exploration planned
- ➤TriSalus operates four FDA-cleared devices and two Letter-to-File devices
TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum
TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum. Management will participate in one-on-one meetings and present a corporate overview on Wednesday, November 11, at 11:30 a.m. ET. Click here for a link to the live webcast.
Get started
Create a free account to read the full story.